Quote: Well, yeah - in nulls after 14 days (arguably one of the breakthroughs could have been noticed at day 14 - but regardless VRUS abstract didn't give equivalent data on breakthroughs or viral load measurements). Has the VRUS drug combo been run in that environment (more than 14 days? In nulls)? Also note that I know of no BMY trial which is a three DAA combo - did I miss something?
They didn't give any data on breakthroughs because there weren't any. As far as measuring the drop in viral load, you do the math
Quote: Has the VRUS drug combo been run in that environment (more than 14 days? In nulls)?
They have not yet tested the combo beyond 14 days or in nulls.
Quote: Also note that I know of no BMY trial which is a three DAA combo - did I miss something?
You used a three drug DAA in your example. I never suggested BMY tried such a trial.
Quote: So you are assuming both that if you add a 3rd DAA you can both improve SVR and(!!!) shorten duration of treatment. That seems a leap too far to me.
News 
Market Data 
Discover 
AI
